| Gene |
[APP](/genes/app) |
| UniProt |
P05067 |
| PDB |
1IYT, 1BA4, 2BEG, 5OQV |
| Mol. Weight |
4 kDa (Aβ40/42) |
| Localization |
Extracellular, membrane-associated |
| Family |
[Amyloid precursor protein](/entities/app-protein) family |
| Diseases |
[Alzheimer's Disease](/diseases/alzheimers), [Cerebral Amyloid Angiopathy](/diseases/cerebral-amyloid-angiopathy) |
Amyloid-beta (Aβ) is a peptide fragment derived from the proteolytic processing of the Amyloid Precursor Protein (APP))))))), encoded by the APP gene on chromosome 21. It is a 40-42 amino acid peptide that plays a central role in the pathogenesis of Alzheimer's disease (AD) and related amyloidopathies.
flowchart TD
subgraph APP_Processing
A["A PP Protein"] --> B{"Non-amyloidogenic"}
A --> C{"Amyloidogenic"}
end
B --> Dα-secretase cleavage
D --> EsAPPα - N["europrotective"]
D --> FCTFα
C --> Gβ-secretase BAC ["E1"]
G --> HsAPPβ
H --> Iγ-secretase
I --> JAβ M["onomers"]
J --> K["Oligomers"]
K --> L["Protofibrils"]
L --> M["Fibrils"]
M --> N["Amyloid Plaques"]
J -->|"Aβ40"| O~80-90%
J -->|"Aβ42"| P~5-10% - M["ore toxic"]
K -->|"Toxic"| Q["Synaptic Dysfunction"]
K -->|"Toxic"| R["Oxidative Stress"]
K -->|"Toxic"| S["Calcium Dysregulation"]
K -->|"Toxic"| T["Neuroinflammation"]
APP can be processed through two mutually exclusive pathways:
- Non-amyloidogenic pathway: α-secretase cleaves APP within the Aβ sequence, precluding Aβ formation. This pathway produces soluble APPα (sAPPα) and a membrane-bound C-terminal fragment.
- Amyloidogenic pathway: β-secretase (BACE1) cleaves APP at the N-terminus of Aβ, followed by γ-secretase cleavage at the C-terminus, releasing Aβ peptides of various lengths (Aβ38, Aβ40, Aβ42, Aβ43).
The Aβ42 isoform is more hydrophobic and aggregation-prone than Aβ40, making it the primary species found in amyloid plaques.
See also: APP Amyloid Pathway.
¶ Primary Sequence and Domains
Amyloid-beta peptides are derived from the transmembrane domain of APP, with the Aβ sequence spanning residues 681-770 of the APP770 isoform. The peptide contains:
- N-terminal region (1-16): Highly hydrophilic, forms the "soft" segment that initiates aggregation
- Central hydrophobic core (17-21, KLVFF): Critical for fibril formation, known as the "KLVFF" motif
- C-terminal region (22-40/42): Hydrophobic, drives membrane association and aggregation
¶ Secondary and Tertiary Structure
In solution, monomeric Aβ adopts a random coil conformation. Upon aggregation, it transitions to:
- β-sheet structure: Cross-β architecture with strands perpendicular to the fibril axis
- Hydrophobic interactions: Drive the formation of the steric zipper
- Salt bridges: Stabilize the fibril core (e.g., D23-K28 ionic interaction)
Cryo-EM studies have revealed multiple Aβ42 fibril morphologies:
- 3-fold symmetric protofilaments (common in sporadic AD)
- 2-fold symmetric dimers (familial AD cases)
- Polymorphic strains: Different conformations associated with distinct disease phenotypes
Available PDB structures include: 1IYT, 1BA4, 2BEG, 5OQV, 7JTL, 7JYY.
The protein's three-dimensional structure can also be explored via the AlphaFold Protein Structure Database.
Aβ undergoes numerous PTMs that modulate its aggregation and toxicity:
- Ser8: phosphorylation reduces aggregation
- Ser26: affects membrane interactions
- Tyrosine10: nitration enhances toxicity
- N-terminally truncated species (AβpE3, AβpE11): More aggregation-prone, found in plaques
- C-terminally truncated species (Aβ1-38): Less toxic, may be protective
- Asp7 isomerization: Affects aggregation kinetics
- Asp23 isomerization: Alters fibril structure
- Methionine35 oxidation: Reduces aggregation but increases toxicity of oligomers
- Histidine oxidation: Modifies metal binding
- Advanced glycation end products (AGEs): Cross-link Aβ, enhance aggregation
- Found in AD brain: Correlates with disease severity
¶ Aggregation and Toxicity
Aβ aggregation follows a nucleation-dependent polymerization mechanism (also called "seeded growth"):
- Lag phase: Monomers slowly form unstable oligomers
- Nucleation: Critical nucleus forms (typically 2-6 monomers)
- Elongation: Rapid addition of monomers to seed
- Saturation: Equilibrium between monomers and fibrils
flowchart TD
AAβ M["onomers"] --> B["Lag Phase"]
B --> C["Nucleation<br/>Critical Seed"]
C --> D["Elongation Phase"]
D --> E["Protofibrils"]
E --> F["Mature Fibrils"]
F --> G["Amyloid Plaques"]
C -->|"Primary nucleation"| H["Soluble Oligomers<br/>ADDLs"]
H -->|"Secondary nucleation"| I["More Oligomers"]
I -->|"Toxic"| J["Synaptic Dysfunction"]
I -->|"Toxic"| K["Oxidative Stress"]
I -->|"Toxic"| L["Calcium Dyshomeostasis"]
I -->|"Toxic"| M["Mitochondrial Dysfunction"]
I -->|"Toxic"| N["Neuroinflammation"]
The central hydrophobic core (CHC, residues 17-21, KLVFF) is critical for:
- Steric zipper formation: Intermolecular β-sheet stacking
- Oligomerization: Dimer/trimer formation
- Fibril elongation: Monomer addition to fibril ends
The C-terminal hydrophobic tail (residues 30-42) drives:
- Membrane association: Hydrophobic interactions with lipid bilayers
- Fibril stability: Inter-protomer hydrogen bonds
Soluble Aβ oligomers (also called Aβ-derived diffusible ligands, ADDLs) are now recognized as the most toxic species, more so than mature fibrils or plaques. Key oligomer species include:
- Dimers: Smallest toxic unit, ~9 kDa
- Trimers: ~13.5 kDa, highly synaptotoxic
- Tetramers: ~18 kDa, may be "off-pathway"
- Dodecamers (Aβ*56): ~56 kDa, disrupts memory in mice
- Large oligomers: >100 kDa, membrane-permeable
Aβ interacts with multiple membrane components:
- Lipid rafts: Aβ accumulates in cholesterol-rich microdomains
- Ion channels: Forms Ca²⁺-permeable pores
- Receptors: Binds to NMDA, AMPA, insulin receptors
- Membrane fluidity: Alters lipid organization
- Synaptic vesicle: Impairs neurotransmitter release
Aβ exerts toxicity through multiple interconnected mechanisms:
-
Synaptic dysfunction: Aβ oligomers bind to synaptic receptors (PrPᶜ, NMDA, mGluR5), impairing long-term potentiation (LTP), reducing dendritic spine density, and disrupting neurotransmitter release
-
Oxidative stress: Aβ accumulation increases reactive oxygen species (ROS) production through:
- Mitochondrial complex III dysfunction
- NADPH oxidase activation
- Metal redox cycling (Fe²⁺/Cu⁺ oxidation)
- Lipid peroxidation
-
Neuroinflammation: Aβ activates microglia and astrocytes through:
- TLR2/4 pattern recognition receptor activation
- NLRP3 inflammasome activation
- Cytokine/chemokine release (IL-1β, TNF-α, IL-6)
- Chronic inflammation contributes to neurodegeneration
-
Calcium dysregulation: Aβ forms calcium-permeable channels in membranes:
- Uncontrolled Ca²⁺ influx
- Mitochondrial calcium overload
- Calpain activation
- Apoptosis signaling
-
Mitochondrial dysfunction: Aβ localizes to mitochondria:
- Impairs complex IV activity
- Reduces ATP production
- Increases ROS
- Triggers mitophagy deficits
-
Endoplasmic reticulum stress: Aβ disrupts protein folding:
- UPR activation
- CHOP-mediated apoptosis
- Calcium store depletion
-
Autophagy impairment: Aβ disrupts autophagic flux:
- mTORC1 hyperactivation
- Lysosomal dysfunction
- Autophagosome accumulation
See also: Amyloid Aggregation, Amyloid Hypothesis, and Amyloid-Tau Synergistic Interaction.
¶ APP Processing and Genetic Risk
Amyloid precursor protein (APP) processing determines Aβ production:
The non-amyloidogenic pathway is the default processing route in healthy brains:
- α-secretase cleavage: ADAM10/ADAM17 cleave APP at residue 16 (within the Aβ sequence)
- sAPPα release: Produces soluble APPα, which has neuroprotective properties
- CTFα formation: Creates a membrane-bound C-terminal fragment
- γ-secretase processing: CTFα is further processed to p3 peptide (non-amyloidogenic)
The sAPPα fragment:
- Promotes neurite outgrowth
- Enhances synaptic plasticity
- Has anti-inflammatory properties
- Protects against excitotoxicity
The amyloidogenic pathway generates Aβ peptides:
- β-secretase (BACE1) cleavage: First cleavage at residue 1 of Aβ (APP residue 681)
- sAPPβ release: Soluble APPβ fragment
- CTFβ formation: C-terminal membrane fragment
- γ-secretase cleavage: Multiple cleavage sites produce Aβ38-43
γ-secretase cleavage sites:
- ε-site: Releases Aβ46-49 (longer fragments)
- γ-site: Produces Aβ38-43 isoforms
- ζ-site: Alternative cleavage
| Mutation |
Effect |
Phenotype |
| Swedish (K670N/M671L) |
↑ Aβ production |
Early-onset AD |
| Arctic (E22G) |
↑ Oligomerization |
Aggressive AD |
| London (V717I) |
↑ Aβ42/Aβ40 |
Early-onset AD |
| Flemish (A692G) |
↑ Aβ40 |
CAA + AD |
| Dutch (E693Q) |
↑ Aβ aggregation |
Severe CAA |
| Italian (E693K) |
↑ Aggregation |
CAA |
| Iowa (D694N) |
↑ Aggregation |
CAA + AD |
- A673V (Icelandic): Reduces Aβ production by 40%, carriers have 5x lower AD risk
- A673T: Protective in vitro
- Duplication syndrome: APP triplication causes early-onset AD with CAA
- Down syndrome: Extra APP copy leads to early Aβ accumulation
- BIN1: Affects Aβ trafficking and aggregation
- PICALM: Modulates endocytosis and Aβ production
- CLU (Clusterin): Aβ chaperone, genetic risk factor
- ABCA7: Aβ clearance, lipid metabolism
The brain has multiple pathways for Aβ clearance:
-
Neprilysin (NEP): Primary Aβ-degrading enzyme in brain
- Expression decreases with age
- NEP overexpression reduces plaques in mice
- AAV-mediated NEP delivery in clinical trials
-
Insulin-degrading enzyme (IDE): Aβ and insulin degradation
- Located in cytoplasm, mitochondria, and extracellular space
- Genetic variants affect AD risk
-
Matrix metalloproteinases (MMPs): MMP-2, MMP-9 degrade Aβ
- Activated in glia
- Increased in AD brain
-
Plasmin: Broad-spectrum protease
- Activated by tPA
- Lower in AD CSF
-
Cathepsins: Lysosomal proteases
- Cathepsin B: Inhibited by cystatin C
- Cathepsin D: Active in lysosomes
Microglia clear Aβ through:
-
Receptor-mediated phagocytosis
- TLRs (Toll-like receptors)
- RAGE (Receptor for Advanced Glycation Endproducts)
- SR-A (Scavenger Receptor A)
- CD36 (class B scavenger receptor)
-
Autophagy-lysosomal degradation
- LC3-associated phagocytosis (LAP)
- PICALM involvement
- Damaged lysosomes impair clearance
-
Aβ export across the blood-brain barrier
- LRP1 (Low-density lipoprotein receptor-related protein 1)
- P-glycoprotein (ABCB1)
- Age-related export decline
Peripheral Aβ affects brain Aβ through the "peripheral sink" hypothesis:
- Liver and kidney clearance: Circulating Aβ degradation
- Monocyte/macrophage uptake: Phagocytic clearance
- Antibody-mediated clearance: Immunotherapy mechanisms
- LDL receptor family: Aβ binding and clearance
¶ Sleep and Glymphatic Clearance
The glymphatic system is critical for Aβ clearance:
- Astrocytic AQP4 channels: Water flux
- Arterial pulsation: Driving force
- Sleep-dependent clearance: 60% more clearance during sleep
- Aβ diurnal variation: Higher during wakefulness
- Sleep disruption: Increases Aβ accumulation
¶ Cellular and Animal Models
- Cell lines: CHO, HEK293, N2a for APP processing
- Primary neurons: Mouse, rat, human
- iPSC-derived neurons: Patient-specific models
- 3D neuronal cultures: Cerebral organoids
- Blood-brain barrier models: Transwell systems
| Model |
Mutation |
Aβ Profile |
Plaques |
Notes |
| APP/PS1 |
APP Swe + PS1ΔE9 |
Aβ40↑, Aβ42↑ |
Yes |
Common model |
| 5xFAD |
3 APP + 2 PS1 |
Aβ42↑↑ |
Yes |
Aggressive |
| APP23 |
APP Swe |
Aβ40↑ |
Yes |
Swiss colony |
| Tg2576 |
APP Swe |
Aβ40↑ |
Yes |
Memory deficits |
| J20 |
APP Indiana + Swedish |
Aβ42↑ |
Yes |
Synaptic loss |
| 3xTG |
APP + tau + PS1 |
Aβ40/42 + tau |
Yes |
AD-like |
- Aβ oligomers cause synaptic dysfunction before plaques
- Microglial activation precedes plaque formation
- Tau pathology is required for full neurodegeneration
- Aβ vaccination reduces plaques but not always cognitive decline
- C. elegans: Simplest model for aggregation studies
- Drosophila: Express Aβ in fly brain
- Zebrafish: Transparent model for development
- NHPs (non-human primates): Closest to human physiology
¶ Clinical Trials and Therapeutic Challenges
Aβ-targeting therapies have faced challenges:
Completed trials (unsuccessful):
- Passive immunization (bapineuzumab, solanezumab)
- Active immunization (AN1792)
- γ-secretase inhibitors
- BACE1 inhibitors
Lessons learned:
- Early intervention may be critical
- Biomarker selection matters
- Target engagement necessary
- Combination approaches needed
Ongoing strategies:
- Anti-oligomer antibodies
- Small molecule aggregation inhibitors
- Vaccine approaches with improved design
- Aβ clearance enhancement
See also: Anti-Amyloid Therapeutics.
Amyloid-beta (Aβ) is implicated in the following neurodegenerative conditions:
The amyloid cascade hypothesis, proposed by Hardy and Higgins in 1992, remains the dominant framework for understanding AD pathogenesis:
- Aβ accumulation precedes tau pathology
- Aβ triggers downstream tau hyperphosphorylation
- Neurofibrillary tangles form
- Neuronal loss and cognitive decline follow
Despite clinical trial failures, the hypothesis has evolved:
- Modified view: Aβ triggers, but tau drives neurodegeneration
- Oligomer-centric: Soluble oligomers, not plaques, are toxic
- Temporal model: Aβ effects are age-dependent and cumulative
Misfolding, aggregation, or dysfunction of Amyloid-beta (Aβ) contributes to neuronal damage through various mechanisms including proteotoxic stress, disrupted cellular signaling, and neuroinflammation.
Individuals with Down syndrome develop AD-like pathology by age 40-50:
- APP triplication: Chromosome 21 carries extra APP copy
- Aβ overexpression: 1.5x normal Aβ production
- Early plaques: Aβ plaques appear in 20s-30s
- Dementia risk: 50-70% develop dementia by age 60+
See also: Down Syndrome Alzheimer's Disease.
Amyloid-beta (Aβ) represents an important therapeutic target. Multiple drug development programs are exploring strategies to:
- Verubecestat (MK-8931): Failed in Phase 3 — too much target engagement caused cognitive worsening
- Atabecestat: Failed due to liver toxicity
- Challenge: BACE1 processes many other substrates critical for synaptic function
- Notch-sparing modulators: Reduce Aβ42 production without Notch inhibition
- Chronic use potential: More tolerable than inhibitors
- Natural compounds: Some NSAIDs act as GSMs
- Lecanemab (Leqembi): FDA-approved, binds Aβ protofibrils, 27% slowing of cognitive decline
- Donanemab (Kisunla): FDA-approved, targets pyroglutamate-modified Aβ
- Gantenerumab: Failed in Phase 3 (Gradear)
- Aduhelm (aducanumab): Controversial FDA approval, withdrawn from market
- ACI-35 (Lipidated tau): Phase 2 — anti-phospho-tau vaccine
- ABvac40: Phase 2 — targets Aβ40
- CAD106: Phase 2/3 — targets Aβ1-6
- Curcumin: Natural polyphenol, binds Aβ, anti-inflammatory
- Epigallocatechin gallate (EGCG): Green tea catechin, disrupts oligomers
- Broussoflavonol: Natural compound in paper mulberry
- Anle138b: Triple aromatic compound, blocks oligomer formation
- Clioquinol: Cu/Zn chelator, reduces Aβ toxicity
- PBT2: Second-generation chelator, failed in Phase 2
- Anti-inflammatory: Anti-TNFα, NSAIDs (failed in prevention trials)
- Neuroprotective: AMPA modulators, neurotrophic factors
- Synaptic restoration: BDNF analogs, M1 agonists
- Metabolic support: GLP-1 agonists, metabolic enhancers
- ACI-302: Preferentially targets toxic oligomers
- BACI: Bispecific antibody approach
- Neprilysin enhancement: Endogenous Aβ-degrading enzyme
- IDE (insulin-degrading enzyme): Aβ clearance
- Matrix metalloproteinases (MMPs): Aβ degradation
- Anti-peripheral Aβ antibodies: "Peripheral sink" hypothesis
- Albumin-based approaches: Bind plasma Aβ, shift equilibrium
See also: Anti-Amyloid Therapeutics, Amyloid-Beta 40 Biomarker, Amyloid-Beta 42/40 Ratio.
- The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science, 2002.
- Amyloid-beta peptide — a chemist's perspective. Angew Chem Int Ed, 2009.
- Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Brain, 2008.
- Lecanemab in Early Alzheimer's Disease. NEJM, 2022.
Multiple Aβ peptide species exist due to alternative γ-secretase cleavage:
| Species |
Length |
Abundance |
Aggregation |
| Aβ37 |
37 aa |
Low |
Low |
| Aβ38 |
38 aa |
~10% |
Low |
| Aβ40 |
40 aa |
~80-90% |
Moderate |
| Aβ42 |
42 aa |
~5-10% |
High |
| Aβ43 |
43 aa |
Trace |
Very high |
- Elevated Aβ42/Aβ40 ratio increases aggregation risk
- APP mutations can shift production toward Aβ42
- The ratio is a biomarker for AD risk
- N-terminally truncated Aβ (pE3-Aβ42, pE11-Aβ42)
- More aggregation-prone
- Found in early-onset AD and CAA
| Biomarker |
Change in AD |
Clinical Utility |
| Aβ40 |
Decreased |
Reflects global Aβ production |
| Aβ42 |
Decreased |
Reflects plaque deposition |
| Aβ42/Aβ40 ratio |
Decreased |
Improved diagnostic accuracy |
| Total tau (t-tau) |
Increased |
Neurodegeneration marker |
| Phospho-tau (p-tau) |
Increased |
Tau pathology marker |
- Aβ42/Aβ40 ratio: Plasma ratio shows promise for screening
- p-tau181, p-tau217, p-tau231: Phospho-tau isoforms correlate with Aβ burden
- Neurofilament light (NfL): Axonal damage marker
- GFAP: Astrocyte activation marker
- Amyloid PET (PiB, Florbetapir, Florbetaben): Visualizes plaque burden
- Florbetapir F-18 (Amyvid): FDA-approved for clinical use
- Amyloid load correlates poorly with cognition: Supports oligomer hypothesis
See also: Amyloid-Beta 42/40 Ratio, Amyloid PET Imaging, p-tau217.